GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (LSE:RGT) » Definitions » Debt-to-Asset

Argent Biopharma (LSE:RGT) Debt-to-Asset : 3.06 (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Argent Biopharma Debt-to-Asset?

Argent Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was £4.32 Mil. Argent Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was £0.37 Mil. Argent Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was £1.53 Mil. Argent Biopharma's debt to asset for the quarter that ended in Dec. 2024 was 3.06.


Argent Biopharma Debt-to-Asset Historical Data

The historical data trend for Argent Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma Debt-to-Asset Chart

Argent Biopharma Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.28 0.10 0.06 0.10

Argent Biopharma Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.06 0.03 0.10 3.06

Competitive Comparison of Argent Biopharma's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argent Biopharma's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Argent Biopharma's Debt-to-Asset falls into.


;
;

Argent Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Argent Biopharma's Debt-to-Asset for the fiscal year that ended in Jun. 2024 is calculated as

Argent Biopharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argent Biopharma  (LSE:RGT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Argent Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Argent Biopharma Business Description

Traded in Other Exchanges
Address
295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008
Argent Biopharma Ltd is a drug discovery company that addresses unmet medical needs. The company focuses on multidisciplinary methods with nanotechnology, developing multi-target therapies for comprehensive disease management, especially in the central nervous system and immunology treatments. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury, and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others.